{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T04:33:14Z","timestamp":1769747594927,"version":"3.49.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["212303"],"award-info":[{"award-number":["212303"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hyperphosphatemia is associated with increased mortality and cardiovascular morbidity of end-stage kidney failure (ESKF) patients. Managing serum phosphate in ESKF patients is challenging and mostly based on limiting intestinal phosphate absorption with low phosphate diets and phosphate binders (PB). In a multi-centric, double-blinded, placebo-controlled study cohort of maintenance hemodialysis patients with hyperphosphatemia, we demonstrated the efficacy of nicotinamide modified release (NAMR) formulation treatment in addition to standard PB therapy in decreasing serum phosphate. Here we aimed to assess the relationship between phosphate, FGF23, inflammation and iron metabolism in this cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We measured the plasma concentrations of intact fibroblast growth factor 23 (iFGF23) and selected proinflammatory cytokines at baseline and Week 12 after initiating treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We observed a strong correlation between iFGF23 and cFGF23 (C-terminal fragment plus iFGF23). We identified iFGF23 as a better predictor of changes in serum phosphate induced by NAMR and PB treatment compared with cFGF23. Recursive partitioning revealed at baseline and Week 12, that iFGF23 and cFGF23 together with T50 propensity were the most important predictors of serum phosphate, whereas intact parathyroid hormone (iPTH) played a minor role in this model. Furthermore, we found serum phosphate and iPTH as the best predictors of iFGF23 and cFGF23. Sex, age, body mass index, and markers of inflammation and iron metabolism had only a minor impact in predicting FGF23.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Lowering serum phosphate in ESKF patients may depend highly on iFGF23 which is correlated to cFGF23 levels. Serum phosphate was the most important predictor of plasma FGF23 in this ESKF cohort.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfad040","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T15:50:30Z","timestamp":1678377030000},"page":"1622-1633","source":"Crossref","is-referenced-by-count":9,"title":["Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients"],"prefix":"10.1093","volume":"16","author":[{"given":"Daniela","family":"Egli-Spichtig","sequence":"first","affiliation":[{"name":"Institute of Physiology, University of Zurich , 8057 Zurich , Switzerland ,"},{"name":"and National Center of Competence in Research NCCR Kidney.CH , 8057 Zurich , Switzerland ,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad Kamal","family":"Hamid","sequence":"additional","affiliation":[{"name":"Institute of Physiology, University of Zurich , 8057 Zurich , Switzerland ,"},{"name":"and National Center of Competence in Research NCCR Kidney.CH , 8057 Zurich , Switzerland ,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Maria Pastor","family":"Arroyo","sequence":"additional","affiliation":[{"name":"Institute of Physiology, University of Zurich , 8057 Zurich , Switzerland ,"},{"name":"and National Center of Competence in Research NCCR Kidney.CH , 8057 Zurich , Switzerland ,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Ketteler","sequence":"additional","affiliation":[{"name":"Robert Bosch Hospital, Department of General Internal Medicine and Nephrology , Stuttgart , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Wiecek","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice , Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander R","family":"Rosenkranz","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Medical University of Graz , Graz , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Pasch","sequence":"additional","affiliation":[{"name":"Calciscon AG , 2503 Biel , Switzerland"},{"name":"Department of Nephrology , Lindenhofspital, 3012 Bern , Switzerland"},{"name":"Department of Physiology and Pathophysiology, Johannes Kepler University Linz , Linz , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horst","family":"Lorenz","sequence":"additional","affiliation":[{"name":"Buero fuer Biometrie und Statistik , Neuberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkhard","family":"Hellmann","sequence":"additional","affiliation":[{"name":"MEDICE Arzneimittel P\u00fctter GmbH & Co KG , Iserlohn , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Karus","sequence":"additional","affiliation":[{"name":"MEDICE Arzneimittel P\u00fctter GmbH & Co KG , Iserlohn , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Ammer","sequence":"additional","affiliation":[{"name":"MEDICE Arzneimittel P\u00fctter GmbH & Co KG , Iserlohn , Germany"},{"name":"Department of Medicine D, Division of General Internal Medicine, Nephrology and Rheumatology, University Hospital of M\u00fcnster , M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1051-9511","authenticated-orcid":false,"given":"Isabel","family":"Rubio-Aliaga","sequence":"additional","affiliation":[{"name":"Institute of Physiology, University of Zurich , 8057 Zurich , Switzerland ,"},{"name":"and National Center of Competence in Research NCCR Kidney.CH , 8057 Zurich , Switzerland ,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9874-8898","authenticated-orcid":false,"given":"Carsten A","family":"Wagner","sequence":"additional","affiliation":[{"name":"Institute of Physiology, University of Zurich , 8057 Zurich , Switzerland ,"},{"name":"and National Center of Competence in Research NCCR Kidney.CH , 8057 Zurich , Switzerland ,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"2023092902525121200_bib1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"2023092902525121200_bib2","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ki.2011.26","article-title":"Phosphate and Klotho","volume":"79","author":"Kuro","year":"2011","journal-title":"Kidney Int"},{"key":"2023092902525121200_bib3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/ndt\/gfs460","article-title":"Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study","volume":"28","author":"Pavik","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902525121200_bib4","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2023092902525121200_bib5","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1161\/CIRCULATIONAHA.105.553198","article-title":"Relation between serum phosphate level and cardiovascular event rate in people with coronary disease","volume":"112","author":"Tonelli","year":"2005","journal-title":"Circulation"},{"key":"2023092902525121200_bib6","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/ndt\/gfv099","article-title":"Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study","volume":"30","author":"Fernandez-Martin","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902525121200_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/IJNRD.S318593","article-title":"Multidisciplinary perspectives of current approaches and clinical gaps in the management of hyperphosphatemia","volume":"14","author":"Vallee","year":"2021","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2023092902525121200_bib8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41581-019-0159-y","article-title":"Mechanisms of phosphate transport","volume":"15","author":"Levi","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2023092902525121200_bib9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2023092902525121200_bib10","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/ki.2013.185","article-title":"Use of phosphate-binding agents is associated with a lower risk of mortality","volume":"84","author":"Cannata-Andia","year":"2013","journal-title":"Kidney Int"},{"key":"2023092902525121200_bib11","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1681\/ASN.2018101058","article-title":"Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: the COMBINE trial","volume":"30","author":"Ix","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2023092902525121200_bib12","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ekir.2020.12.012","article-title":"Efficacy and safety of a novel nicotinamide modified-release formulation in the treatment of refractory hyperphosphatemia in patients receiving hemodialysis-a randomized clinical trial","volume":"6","author":"Ketteler","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023092902525121200_bib13","article-title":"Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase III randomised controlled NOPHOS trial","author":"Ketteler","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902525121200_bib14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cca.2020.03.013","article-title":"FGF23 measurement in chronic kidney disease: what is it really reflecting?","volume":"505","author":"Vervloet","year":"2020","journal-title":"Clin Chim Acta"},{"key":"2023092902525121200_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-physiol-021119-034650","article-title":"Regulation and effects of FGF23 in chronic kidney disease","volume":"82","author":"Musgrove","year":"2020","journal-title":"Annu Rev Physiol"},{"key":"2023092902525121200_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/0004563213510708","article-title":"Fibroblast growth factor 23","volume":"51","author":"Smith","year":"2014","journal-title":"Ann Clin Biochem"},{"key":"2023092902525121200_bib17","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1210\/jc.2012-1811","article-title":"Biological variability of plasma intact and C-terminal FGF23 measurements","volume":"97","author":"Smith","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2023092902525121200_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int"},{"key":"2023092902525121200_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.kint.2018.02.026","article-title":"Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease","volume":"94","author":"Durlacher-Betzer","year":"2018","journal-title":"Kidney Int"},{"key":"2023092902525121200_bib20","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.kint.2019.04.009","article-title":"Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation","volume":"96","author":"Egli-Spichtig","year":"2019","journal-title":"Kidney Int"},{"key":"2023092902525121200_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jbm4.10023","article-title":"A novel distal enhancer mediates inflammation-, PTH-, and early onset murine kidney disease-induced expression of the mouse Fgf23 gene","volume":"2","author":"Onal","year":"2018","journal-title":"JBMR Plus"},{"key":"2023092902525121200_bib22","doi-asserted-by":"crossref","first-page":"E1146","DOI":"10.1073\/pnas.1110905108","article-title":"Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice","volume":"108","author":"Farrow","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023092902525121200_bib23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2459\/JCM.0b013e3283536859","article-title":"Fibroblast growth factor-23 and interleukin-6 are risk factors for left ventricular hypertrophy in peritoneal dialysis patients","volume":"13","author":"Liu","year":"2012","journal-title":"J Cardiovasc Med"},{"key":"2023092902525121200_bib24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1590\/1414-431X20144007","article-title":"Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease","volume":"47","author":"Nascimento","year":"2014","journal-title":"Braz J Med Biol Res"},{"key":"2023092902525121200_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/sji.12392","article-title":"Sclerostin, TNF-alpha and interleukin-18 correlate and are together with Klotho related to other growth factors and cytokines in haemodialysis patients","volume":"83","author":"Almroth","year":"2016","journal-title":"Scand J Immunol"},{"key":"2023092902525121200_bib26","first-page":"110","article-title":"Serum sTWEAK and FGF-23 levels in hemodialysis and renal transplant patients","volume":"8","author":"Eskandari Naji","year":"2017","journal-title":"Int J Organ Transplant Med"},{"key":"2023092902525121200_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2017.02.005","article-title":"Low serum iron is associated with high serum intact FGF23 in elderly men: the Swedish MrOS study","volume":"98","author":"Lewerin","year":"2017","journal-title":"Bone"},{"key":"2023092902525121200_bib28","doi-asserted-by":"crossref","first-page":"e3049","DOI":"10.1097\/MD.0000000000003049","article-title":"High fibroblast growth factor 23 levels associated with low hemoglobin levels in patients with chronic kidney disease stages 3 and 4","volume":"95","author":"Tsai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2023092902525121200_bib29","doi-asserted-by":"crossref","first-page":"e0176984","DOI":"10.1371\/journal.pone.0176984","article-title":"High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients","volume":"12","author":"Honda","year":"2017","journal-title":"PLoS One"},{"key":"2023092902525121200_bib30","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1681\/ASN.2016121350","article-title":"C-terminal fibroblast growth factor 23, iron deficiency, and mortality in renal transplant recipients","volume":"28","author":"Eisenga","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2023092902525121200_bib31","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.3390\/jcm9082640","article-title":"The role of iron and erythropoietin in the association of fibroblast growth factor 23 with anemia in chronic kidney disease in humans","volume":"9","author":"Bielesz","year":"2020","journal-title":"J Clin Med"},{"key":"2023092902525121200_bib32","doi-asserted-by":"crossref","first-page":"e4875","DOI":"10.1210\/clinem\/dgaa665","article-title":"Intact and C-terminal FGF23 assays-do kidney function, inflammation, and low iron influence relationships with outcomes?","volume":"105","author":"Sharma","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2023092902525121200_bib33","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.1038\/s41598-018-25439-z","article-title":"Circulating fibroblast growth factor-23 levels are associated with an increased risk of anemia development in patients with nondialysis chronic kidney disease","volume":"8","author":"Nam","year":"2018","journal-title":"Sci Rep"},{"key":"2023092902525121200_bib34","author":"R Core Team","journal-title":"R: a language and environment for statistical computing"},{"key":"2023092902525121200_bib35","author":"Therneau"},{"key":"2023092902525121200_bib36","doi-asserted-by":"crossref","volume-title":"Classification And Regression Trees","author":"Breiman","DOI":"10.1201\/9781315139470"},{"key":"2023092902525121200_bib37","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1210\/jc.2009-1603","article-title":"Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active","volume":"95","author":"Shimada","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2023092902525121200_bib38","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N Engl J Med"},{"key":"2023092902525121200_bib39","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1359\/jbmr.060507","article-title":"Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women","volume":"21","author":"Burnett","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2023092902525121200_bib40","doi-asserted-by":"crossref","first-page":"11418","DOI":"10.1073\/pnas.1815166116","article-title":"Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation","volume":"116","author":"Takashi","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023092902525121200_bib41","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1210\/en.2008-0877","article-title":"Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression","volume":"150","author":"Ichikawa","year":"2009","journal-title":"Endocrinology"},{"key":"2023092902525121200_bib42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ndt\/gfy061","article-title":"The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia","volume":"34","author":"Block","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902525121200_bib43","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/ndt\/gfy127","article-title":"Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients","volume":"34","author":"Ketteler","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902525121200_bib44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1073\/pnas.0902006107","article-title":"Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation","volume":"107","author":"Goetz","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023092902525121200_bib45","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jsbmb.2006.12.054","article-title":"1,25-Dihydroxyvitamin D3\/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism","volume":"103","author":"Barthel","year":"2007","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2023092902525121200_bib46","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1113\/JP280345","article-title":"1,25(OH)2 vitamin D3 stimulates active phosphate transport but not paracellular phosphate absorption in mouse intestine","volume":"599","author":"Hernando","year":"2021","journal-title":"J Physiol"},{"key":"2023092902525121200_bib47","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/ki.2014.215","article-title":"Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription","volume":"86","author":"Meir","year":"2014","journal-title":"Kidney Int"},{"key":"2023092902525121200_bib48","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.2215\/CJN.08241109","article-title":"Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism","volume":"5","author":"Evenepoel","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023092902525121200_bib49","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1210\/jc.2016-2215","article-title":"Fibroblast growth factor 23 and cause-specific mortality in the general population: the Northern Manhattan Study","volume":"101","author":"Souma","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2023092902525121200_bib50","doi-asserted-by":"crossref","first-page":"eAO5925","DOI":"10.31744\/einstein_journal\/2021AO5925","article-title":"Association between fibroblast growth factor 23 and functional capacity among independent elderly individuals","volume":"19","author":"Araujo","year":"2021","journal-title":"Einstein (Sao Paulo)"},{"key":"2023092902525121200_bib51","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jgs.13951","article-title":"Fibroblast growth factor-23 and frailty in elderly community-dwelling individuals: the Cardiovascular Health Study","volume":"64","author":"Beben","year":"2016","journal-title":"J Am Geriatr Soc"},{"key":"2023092902525121200_bib52","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1248\/bpb.b14-00276","article-title":"Expression of Fgf23 in activated dendritic cells and macrophages in response to immunological stimuli in mice","volume":"38","author":"Masuda","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"2023092902525121200_bib53","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1172\/JCI83470","article-title":"FGF23 signaling impairs neutrophil recruitment and host defense during CKD","volume":"126","author":"Rossaint","year":"2016","journal-title":"J Clin Invest"},{"key":"2023092902525121200_bib54","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MNH.0000000000000514","article-title":"Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease","volume":"28","author":"Babitt","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2023092902525121200_bib55","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.13281211","article-title":"Fibroblast growth factor 23 and Inflammation in CKD","volume":"7","author":"Munoz Mendoza","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023092902525121200_bib56","doi-asserted-by":"crossref","first-page":"e0122885","DOI":"10.1371\/journal.pone.0122885","article-title":"Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults","volume":"10","author":"Hanks","year":"2015","journal-title":"PLoS One"},{"key":"2023092902525121200_bib57","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.kint.2016.10.021","article-title":"Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease","volume":"91","author":"Munoz Mendoza","year":"2017","journal-title":"Kidney Int"},{"key":"2023092902525121200_bib58","doi-asserted-by":"crossref","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"2023092902525121200_bib59","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00359.2016","article-title":"Ironing out the cross talk between FGF23 and inflammation","volume":"312","author":"David","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"2023092902525121200_bib60","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1159\/000489964","article-title":"Ferric citrate decreases fibroblast growth factor 23 and improves erythropoietin","volume":"47","author":"Maruyama","year":"2018","journal-title":"Am J Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfad040\/50212979\/sfad040.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/10\/1622\/51788675\/sfad040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/10\/1622\/51788675\/sfad040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T02:56:20Z","timestamp":1695956180000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/16\/10\/1622\/7075899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":60,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,3,10]]},"published-print":{"date-parts":[[2023,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfad040","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,3,10]]}}}